Gut microbiome and metabolism alterations in schizophrenia with metabolic syndrome severity.
Biomarker
Metabolic syndrome
Multi–omics
Schizophrenia
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
24 Jul 2024
24 Jul 2024
Historique:
received:
25
04
2024
accepted:
16
07
2024
medline:
26
7
2024
pubmed:
26
7
2024
entrez:
25
7
2024
Statut:
epublish
Résumé
Schizophrenia (SCZ) patients undergoing antipsychotic treatment demonstrated a high prevalence and harmful effects of metabolic syndrome (MetS), which acted as the major cause of cardiovascular disease. The major clinical challenge is the lack of biomarkers to identify MetS episodes and prevent further damage, while the mechanisms underlying these drug-induced MetS remain unknown. This study divided 173 participants with SCZ into 3 groups (None, High risk, and MetS, consisting of 22, 88, and 63 participants, respectively). The potential biomarkers were searched based on 16S rRNA gene sequence together with metabolism analysis. Logistic regression was used to test the effects of the genus-metabolites panel on early MetS diagnoses. A genus-metabolites panel, consisting of Senegalimassilia, sphinganine, dihomo-gamma-linolenoylcholine, isodeoxycholic acid, and MG (0:0/22:5/0:0), which involved in sphigolipid metabolism, fatty acid metabolism, secondary bile acid biosynthesis and glycerolipid metabolism, has a great discrimination efficiency to MetS with an area under the curve (AUC) value of 0.911 compared to the None MetS group (P = 1.08E-8). Besides, Senegalimassilia, 3-Hydroxytetradecanoyl carnitine, isodeoxycholic acid, and DG(TXB2/0:0/2:0) distinguished between subgroups robustly and exhibited a potential correlation with the severity of MetS in patients with SCZ, and may act as the biomarkers for early MetS diagnosis. Our multi-omics study showed that one bacterial genus-five lipid metabolites panel is the potential risk factor for MetS in SCZ. Furthermore, Senegalimassilia, 3-Hydroxytetradecanoyl carnitine, isodeoxycholic acid, and DG(TXB2/0:0/2:0) could serve as novel diagnostic markers in the early stage. So, it is obvious that the combination of bacterial genus and metabolites yields excellent discriminatory power, and the lipid metabolism provide new understanding to the pathogenesis, prevention, and therapy for MetS in SCZ.
Sections du résumé
BACKGROUND
BACKGROUND
Schizophrenia (SCZ) patients undergoing antipsychotic treatment demonstrated a high prevalence and harmful effects of metabolic syndrome (MetS), which acted as the major cause of cardiovascular disease. The major clinical challenge is the lack of biomarkers to identify MetS episodes and prevent further damage, while the mechanisms underlying these drug-induced MetS remain unknown.
METHODS
METHODS
This study divided 173 participants with SCZ into 3 groups (None, High risk, and MetS, consisting of 22, 88, and 63 participants, respectively). The potential biomarkers were searched based on 16S rRNA gene sequence together with metabolism analysis. Logistic regression was used to test the effects of the genus-metabolites panel on early MetS diagnoses.
RESULTS
RESULTS
A genus-metabolites panel, consisting of Senegalimassilia, sphinganine, dihomo-gamma-linolenoylcholine, isodeoxycholic acid, and MG (0:0/22:5/0:0), which involved in sphigolipid metabolism, fatty acid metabolism, secondary bile acid biosynthesis and glycerolipid metabolism, has a great discrimination efficiency to MetS with an area under the curve (AUC) value of 0.911 compared to the None MetS group (P = 1.08E-8). Besides, Senegalimassilia, 3-Hydroxytetradecanoyl carnitine, isodeoxycholic acid, and DG(TXB2/0:0/2:0) distinguished between subgroups robustly and exhibited a potential correlation with the severity of MetS in patients with SCZ, and may act as the biomarkers for early MetS diagnosis.
CONCLUSIONS
CONCLUSIONS
Our multi-omics study showed that one bacterial genus-five lipid metabolites panel is the potential risk factor for MetS in SCZ. Furthermore, Senegalimassilia, 3-Hydroxytetradecanoyl carnitine, isodeoxycholic acid, and DG(TXB2/0:0/2:0) could serve as novel diagnostic markers in the early stage. So, it is obvious that the combination of bacterial genus and metabolites yields excellent discriminatory power, and the lipid metabolism provide new understanding to the pathogenesis, prevention, and therapy for MetS in SCZ.
Identifiants
pubmed: 39048972
doi: 10.1186/s12888-024-05969-9
pii: 10.1186/s12888-024-05969-9
doi:
Substances chimiques
Biomarkers
0
Antipsychotic Agents
0
RNA, Ribosomal, 16S
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
529Informations de copyright
© 2024. The Author(s).
Références
Haddad PM, Correll CU. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. Ther Adv Psychopharmacol. 2018;8(11):303–18. https://doi.org/10.1177/2045125318781475 .
doi: 10.1177/2045125318781475
pubmed: 30344997
pmcid: 6180374
Siskind D, McCartney L, Goldschlager R, Kisely S. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2016;209(5):385–92. https://doi.org/10.1192/bjp.bp.115.177261 .
doi: 10.1192/bjp.bp.115.177261
pubmed: 27388573
Marder SR, Cannon TD. Schizophrenia. N Engl J Med. 2019;381(18):1753–61. https://doi.org/10.1056/NEJMra1808803 .
doi: 10.1056/NEJMra1808803
pubmed: 31665579
Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7(1):64–77. https://doi.org/10.1016/s2215-0366(19)30416-x .
doi: 10.1016/s2215-0366(19)30416-x
pubmed: 31860457
pmcid: 7029416
Penninx B, Lange SMM. Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications. Dialogues Clin Neurosci. 2018;20(1):63–73. https://doi.org/10.31887/DCNS.2018.20.1/bpenninx .
doi: 10.31887/DCNS.2018.20.1/bpenninx
pubmed: 29946213
pmcid: 6016046
[Clinical guidelines for prevention and treatment of type 2 diabetes mellitus in the elderly in China (2022 edition)]. Zhonghua nei ke za zhi. 2022;61(1):12–50. https://doi.org/10.3760/cma.j.cn112138-20211027-00751 .
Howes OD, Bhatnagar A, Gaughran FP, Amiel SA, Murray RM, Pilowsky LS. A prospective study of impairment in glucose control caused by clozapine without changes in insulin resistance. Am J Psychiatry. 2004;161(2):361–3. https://doi.org/10.1176/appi.ajp.161.2.361 .
doi: 10.1176/appi.ajp.161.2.361
pubmed: 14754788
pmcid: 3685269
Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet (London, England). 2019;394(10202):939–51. https://doi.org/10.1016/s0140-6736(19)31135-3 .
doi: 10.1016/s0140-6736(19)31135-3
pubmed: 31303314
pmcid: 6891890
Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735–52. https://doi.org/10.1161/circulationaha.105.169404 .
doi: 10.1161/circulationaha.105.169404
pubmed: 16157765
Correll CU, Solmi M, Veronese N, Bortolato B, Rosson S, Santonastaso P, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017;16(2):163–80. https://doi.org/10.1002/wps.20420 .
doi: 10.1002/wps.20420
pubmed: 28498599
pmcid: 5428179
Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry. 2007;68(Suppl 4):8–13.
pubmed: 17539694
Bora E, Akdede BB, Alptekin K. The relationship between cognitive impairment in schizophrenia and metabolic syndrome: a systematic review and meta-analysis. Psychol Med. 2017;47(6):1030–40. https://doi.org/10.1017/s0033291716003366 .
doi: 10.1017/s0033291716003366
pubmed: 28032535
Lindenmayer JP, Khan A, Kaushik S, Thanju A, Praveen R, Hoffman L, et al. Relationship between metabolic syndrome and cognition in patients with schizophrenia. Schizophr Res. 2012;142(1–3):171–6. https://doi.org/10.1016/j.schres.2012.09.019 .
doi: 10.1016/j.schres.2012.09.019
pubmed: 23106932
Cao B, Chen Y, McIntyre RS, Yan LL. Acyl-Carnitine plasma levels and their association with metabolic syndrome in individuals with schizophrenia. Psychiatry Res. 2020;293: 113458. https://doi.org/10.1016/j.psychres.2020.113458 .
doi: 10.1016/j.psychres.2020.113458
pubmed: 32977055
Burghardt KJ, Ellingrod VL. Detection of Metabolic Syndrome in Schizophrenia and Implications for Antipsychotic Therapy Is There a Role for Folate? Mol Diagn Ther. 2013;17(1):21–30. https://doi.org/10.1007/s40291-013-0017-8 .
doi: 10.1007/s40291-013-0017-8
pubmed: 23341251
pmcid: 4077272
Sanna S, van Zuydam NR, Mahajan A, Kurilshikov A, Vila AV, Vosa U, et al. Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases. Nat Genet. 2019;51(4):600-+. https://doi.org/10.1038/s41588-019-0350-x .
doi: 10.1038/s41588-019-0350-x
pubmed: 30778224
pmcid: 6441384
Khasanova AK, Dobrodeeva VS, Shnayder NA, Petrova MM, Pronina EA, Bochanova EN, et al. Blood and Urinary Biomarkers of Antipsychotic-Induced Metabolic Syndrome. Metabolites. 2022;12(8). https://doi.org/10.3390/metabo12080726 .
Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019;25(7):1096–103. https://doi.org/10.1038/s41591-019-0495-2 .
doi: 10.1038/s41591-019-0495-2
pubmed: 31263284
pmcid: 6699990
Vijay-Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, Srinivasan S, et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science (New York, NY). 2010;328(5975):228–31. https://doi.org/10.1126/science.1179721 .
doi: 10.1126/science.1179721
Dabke K, Hendrick G, Devkota S. The gut microbiome and metabolic syndrome. J Clin Investig. 2019;129(10):4050–7. https://doi.org/10.1172/jci129194 .
doi: 10.1172/jci129194
pubmed: 31573550
pmcid: 6763239
Matey-Hernandez ML, Williams FMK, Potter T, Valdes AM, Spector TD, Menni C. Genetic and microbiome influence on lipid metabolism and dyslipidemia. Physiol Genomics. 2018;50(2):117–26. https://doi.org/10.1152/physiolgenomics.00053.2017 .
doi: 10.1152/physiolgenomics.00053.2017
pubmed: 29341867
Liu H, Chen X, Hu X, Niu H, Tian R, Wang H, et al. Alterations in the gut microbiome and metabolism with coronary artery disease severity. Microbiome. 2019;7(1):68. https://doi.org/10.1186/s40168-019-0683-9 .
doi: 10.1186/s40168-019-0683-9
pubmed: 31027508
pmcid: 6486680
Franzosa EA, Sirota-Madi A, Avila-Pacheco J, Fornelos N, Haiser HJ, Reinker S, et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nat Microbiol. 2019;4(2):293–305. https://doi.org/10.1038/s41564-018-0306-4 .
doi: 10.1038/s41564-018-0306-4
pubmed: 30531976
Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics (Oxford, England). 2018;34(17):i884–90. https://doi.org/10.1093/bioinformatics/bty560 .
doi: 10.1093/bioinformatics/bty560
pubmed: 30423086
Magoč T, Salzberg SL. FLASH: fast length adjustment of short reads to improve genome assemblies. Bioinformatics (Oxford, England). 2011;27(21):2957–63. https://doi.org/10.1093/bioinformatics/btr507 .
doi: 10.1093/bioinformatics/btr507
pubmed: 21903629
Edgar RC. UPARSE: highly accurate OTU sequences from microbial amplicon reads. Nat Methods. 2013;10(10):996–8. https://doi.org/10.1038/nmeth.2604 .
doi: 10.1038/nmeth.2604
pubmed: 23955772
Wang Q, Garrity GM, Tiedje JM, Cole JR. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol. 2007;73(16):5261–7. https://doi.org/10.1128/aem.00062-07 .
doi: 10.1128/aem.00062-07
pubmed: 17586664
pmcid: 1950982
Zhao H, Du H, Liu M, Gao S, Li N, Chao Y, et al. Integrative proteomics-metabolomics strategy for pathological mechanism of vascular depression mouse model. J Proteome Res. 2018;17(1):656–69. https://doi.org/10.1021/acs.jproteome.7b00724 .
doi: 10.1021/acs.jproteome.7b00724
pubmed: 29190102
Yu G, Xu C, Zhang D, Ju F, Ni Y. MetOrigin: Discriminating the origins of microbial metabolites for integrative analysis of the gut microbiome and metabolome. iMeta. 2022;1(1):e10. https://doi.org/10.1002/imt2.10 .
doi: 10.1002/imt2.10
pubmed: 38867728
pmcid: 10989983
Lim K, Peh OH, Yang ZX, Rekhi G, Rapisarda A, See YM, et al. Large-scale evaluation of the Positive and Negative Syndrome Scale (PANSS) symptom architecture in schizophrenia. Asian J Psychiatr. 2021;62:102732. https://doi.org/10.1016/j.ajp.2021.102732 .
doi: 10.1016/j.ajp.2021.102732
pubmed: 34118560
Adamberg K, Adamberg S, Emits K, Larionova A, Voor T, Jaagura M, et al. Composition and metabolism of fecal microbiota from normal and overweight children are differentially affected by melibiose, raffinose and raffinose-derived fructans. Anaerobe. 2018;52:100–10. https://doi.org/10.1016/j.anaerobe.2018.06.009 .
doi: 10.1016/j.anaerobe.2018.06.009
pubmed: 29935270
Garcia-Beltran C, Malpique R, Carbonetto B, Gonzalez-Torres P, Henares D, Brotons P, et al. Gut microbiota in adolescent girls with polycystic ovary syndrome: effects of randomized treatments. Pediatr Obes. 2021;16(4):e12734. https://doi.org/10.1111/ijpo.12734 .
doi: 10.1111/ijpo.12734
pubmed: 32989872
Gao K, Yang R, Zhang P, Wang ZY, Jia CX, Zhang FL, et al. Effects of Qijian mixture on type 2 diabetes assessed by metabonomics, gut microbiota and network pharmacology. Pharmacol Res. 2018;130:93–109. https://doi.org/10.1016/j.phrs.2018.01.011 .
doi: 10.1016/j.phrs.2018.01.011
pubmed: 29391233
Yang M, Nickels JT. MOGAT2: A New Therapeutic Target for Metabolic Syndrome. Diseases. 2015;3(3):176–92. https://doi.org/10.3390/diseases3030176 .
doi: 10.3390/diseases3030176
pubmed: 28943619
pmcid: 5548241
Choi CS, Savage DB, Kulkarni A, Yu XX, Liu ZX, Morino K, et al. Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance. J Biol Chem. 2007;282(31):22678–88. https://doi.org/10.1074/jbc.M704213200 .
doi: 10.1074/jbc.M704213200
pubmed: 17526931
Turner N, Kowalski GM, Leslie SJ, Risis S, Yang C, Lee-Young RS, et al. Distinct patterns of tissue-specific lipid accumulation during the induction of insulin resistance in mice by high-fat feeding. Diabetologia. 2013;56(7):1638–48. https://doi.org/10.1007/s00125-013-2913-1 .
doi: 10.1007/s00125-013-2913-1
pubmed: 23620060
Summers SA, Chaurasia B. Metabolic Messengers: ceramides. Nat Metab. 2019;1(11):1051–8. https://doi.org/10.1038/s42255-019-0134-8 .
doi: 10.1038/s42255-019-0134-8
pubmed: 32694860
pmcid: 7549391
Wasserman AH, Venkatesan M. Bioactive Lipid Signaling in Cardiovascular Disease, Development, and Regeneration. Cells. 2020;9(6):1391. https://doi.org/10.3390/cells9061391 .
doi: 10.3390/cells9061391
pubmed: 32503253
pmcid: 7349721
Jornayvaz FR, Birkenfeld AL, Jurczak MJ, Kanda S, Guigni BA, Jiang DC, et al. Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2. Proc Natl Acad Sci U S A. 2011;108(14):5748–52. https://doi.org/10.1073/pnas.1103451108 .
doi: 10.1073/pnas.1103451108
pubmed: 21436037
pmcid: 3078388
Cao B, Wang D, Pan Z, Brietzke E, McIntyre RS, Musial N, et al. Characterizing acyl-carnitine biosignatures for schizophrenia: a longitudinal pre- and post-treatment study. Transl Psychiatry. 2019;9(1):19. https://doi.org/10.1038/s41398-018-0353-x .
doi: 10.1038/s41398-018-0353-x
pubmed: 30655505
pmcid: 6336814
Waagsbo B, Svardal A, Ueland T, Landro L, Oktedalen O, Berge RK, et al. Low levels of short- and medium-chain acylcarnitines in HIV-infected patients. Eur J Clin Invest. 2016;46(5):408–17. https://doi.org/10.1111/eci.12609 .
doi: 10.1111/eci.12609
pubmed: 26913383
Liu KH, Owens JA. Microbial metabolite delta-valerobetaine is a diet-dependent obesogen. Nat Metab. 2021;3(12):1694–705. https://doi.org/10.1038/s42255-021-00502-8 .
doi: 10.1038/s42255-021-00502-8
pubmed: 34931082
pmcid: 8711632
Liepinsh E, Makrecka-Kuka M, Volska K, Kuka J, Makarova E, Antone U, et al. Long-chain acylcarnitines determine ischaemia/reperfusion-induced damage in heart mitochondria. Biochem J. 2016;473(9):1191–202. https://doi.org/10.1042/BCJ20160164 .
doi: 10.1042/BCJ20160164
pubmed: 26936967
Sun L, Liang L, Gao X, Zhang H, Yao P, Hu Y, et al. Early Prediction of Developing Type 2 Diabetes by Plasma Acylcarnitines: A Population-Based Study. Diabetes Care. 2016;39(9):1563–70. https://doi.org/10.2337/dc16-0232 .
doi: 10.2337/dc16-0232
pubmed: 27388475